Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 791 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brain Tumor Recurrent Clear all
Not listed Phase 1 Interventional

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

NCT00003073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
liposomal cytarabine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

NCT00600054
View directory record Official record
Conditions
Recurrent Diffuse Pontine Gliomas
Interventions
nimotuzumab (anti EGFR humanized monoclonal antibody)
Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
3 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 19, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

NCT00813592
View directory record Official record
Conditions
Cancer
Interventions
SOM230B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

NCT00617539
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional

SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy

NCT00004868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
semaxanib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

NCT01290692
View directory record Official record
Conditions
Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
Interventions
TVI-Brain-1
Biological
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

High Light and Low Light Dose PDT in Glioma

NCT00118222
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
porfimer sodium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

CCI-779 in Treating Patients With Advanced Solid Tumors

NCT00003712
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
2
States / cities
Rochester, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

NCT02271711
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions
Laboratory Biomarker Analysis, Natural Killer Cell Therapy
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

NCT00112866
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
cilengitide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00138216
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, temozolomide, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

NCT00883298
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
Interventions
temozolomide and bevacizumab
Drug
Lead sponsor
Center for Neurosciences, Tucson
Other
Eligibility
18 Years to 83 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 19, 2026, 5:31 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

NCT07132190
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Young Patients With Gliomas

NCT00238264
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
radiation therapy
Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
127
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 19, 2026, 5:31 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

NCT02062827
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
Interventions
M032 (NSC 733972)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

NCT00064779
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

NCT00002988
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, irinotecan hydrochloride
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Results available

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880
View directory record Official record
Conditions
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
Interventions
Pharmacological Study, Selinexor
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

NCT00075491
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
fenretinide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 19, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 19, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 5:31 PM EDT